Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 12/20 | 0.70 |
| ▸ | ADORA2A | P29274 | 10/20 | 0.70 |
| ▸ | ADORA1 | P30542 | 10/20 | 0.70 |
| ▸ | PPARD | Q03181 | 2/20 | 0.56 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6013498 | 0.86 | ADORA3 (0.68) | ADORA3ADORA2AADORA1PPARDPPARG | |
| SCHEMBL5829486 | 0.73 | ADORA3 (1.00) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL27586063 | 0.73 | ADORA3 (0.74) | ADORA3ADORA2AADORA1ADORA2B | |
| SCHEMBL3060344 | 0.72 | ADORA3 (0.73) | ADORA3ADORA2AADORA1PPARDADORA2B | |
| SCHEMBL3060342 | 0.72 | ADORA3 (0.73) | ADORA3ADORA2AADORA1PPARDADORA2B | |
| SCHEMBL22349409 | 0.72 | CDK1 (0.73) | ADORA3ADORA2AADORA1 | |
| SCHEMBL29501881 | 0.72 | CDK1 (0.73) | ADORA3ADORA2AADORA1 | |
| SCHEMBL24414330 | 0.72 | ADORA2A (1.00) | ADORA3ADORA2AADORA1PPARDPPARG | |
| SCHEMBL13298748 | 0.72 | ADORA2A (1.00) | ADORA3ADORA2AADORA1PPARDPPARG | |
| SCHEMBL13318025 | 0.72 | ADORA2A (1.00) | ADORA3ADORA2AADORA1PPARDPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7087589-B2 | Methanocarba cycloakyl nucleoside analogues | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2006-08-08 | — | — | US | disclosed |
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | HEALTH AND HUMAN SERVICES, GOVERNMENT OF THE UNITED STATES OF AMERICA, THE, REPRESENTED BY THE SECRETARY, DEPARTMENT OF | 2003-11-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030216412-A1 | Methanocarba cycloakyl nucleoside analogues | P2RY1, ADORA1, ADORA2A | ADORA3 4/4885ADORA2A 3/4885ADORA1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.